DNA methylation and cardiovascular disease in humans: a systematic review and database of known CpG methylation sites

Abstract

Background Cardiovascular disease (CVD) is the leading cause of death worldwide and considered one of the most environmentally driven diseases. The role of DNA methylation in response to the individual exposure for the development and progression of CVD is still poorly understood and a synthesis of the evidence is lacking. Results A systematic review of articles examining measurements of DNA cytosine methylation in CVD was conducted in accordance with PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. The search yielded 5,563 articles from PubMed and CENTRAL databases. From 99 studies with a total of 87,827 individuals eligible for analysis, a database was created combining all CpG-, gene- and study-related information. It contains 74,580 unique CpG sites, of which 1452 CpG sites were mentioned in ≥ 2, and 441 CpG sites in ≥ 3 publications. Two sites were referenced in ≥ 6 publications: cg01656216 (near ZNF438) related to vascular disease and epigenetic age, and cg03636183 (near F2RL3) related to coronary heart disease, myocardial infarction, smoking and air pollution. Of 19,127 mapped genes, 5,807 were reported in ≥ 2 studies. Most frequently reported were TEAD1 (TEA Domain Transcription Factor 1) and PTPRN2 (Protein Tyrosine Phosphatase Receptor Type N2) in association with outcomes ranging from vascular to cardiac disease. Gene set enrichment analysis of 4,532 overlapping genes revealed enrichment for Gene Ontology molecular function “DNA-binding transcription activator activity” (q = 1.65 × 10–11) and biological processes “skeletal system development” (q = 1.89 × 10–23). Gene enrichment demonstrated that general CVD-related terms are shared, while “heart” and “vasculature” specific genes have more disease-specific terms as PR interval for “heart” or platelet distribution width for “vasculature.” STRING analysis revealed significant protein–protein interactions between the products of the differentially methylated genes (p = 0.003) suggesting that dysregulation of the protein interaction network could contribute to CVD. Overlaps with curated gene sets from the Molecular Signatures Database showed enrichment of genes in hemostasis (p = 2.9 × 10–6) and atherosclerosis (p = 4.9 × 10–4). Conclusion This review highlights the current state of knowledge on significant relationship between DNA methylation and CVD in humans. An open-access database has been compiled of reported CpG methylation sites, genes and pathways that may play an important role in this relationship.

Epigenetics of Early Cardiometabolic Disease: Mechanisms and Precision Medicine

“…Two CpG sites were referenced in at least 6 publications and were related to vascular disease and epigenetic age (cg01656216 near ZNF438 ) and coronary heart disease, myocardial infarction, smoking, and air pollution (cg03636183 near F2RL3 ). 13 These results highlight the potential of DNA methylation as a rich source of biomarkers for cardiovascular diseases.…”

Reduced DNMT1 levels induce cell apoptosis via upregulation of METTL3 in cardiac hypertrophy

“…DNA methylation is involved in cellular progression, including tumorigenesis, cell development, metastasis, apoptosis, cell cycle, and growth [ 29 ]. Increasing evidence indicates that DNA methylation influences the occurrence and development of human diseases [ 30 , 31 ]. However, the effects and molecular mechanisms of DNA methylation in hypertrophy remain controversial.…”

Epigenetic mechanisms of particulate matter exposure: air pollution and hazards on human health

“…A recent systematic review found DNA methylation sites associated with CVD and PM 2.5 . CpG sites cgo1656216 (near ZNF438 ) and cgo3636183 (near F2RL3 ) were significantly associated with CVD and air pollution ( Krolevets et al, 2023 ). Similarly, some clinical trials have shown the association between DNA methylation, CVD, and PM.…”